These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
291 related items for PubMed ID: 9125276
1. Pharmacokinetics of estradiol and of estrone during repeated transdermal or oral administration of estradiol. Setnikar I, Rovati LC, Vens-Cappell B, Hilgenstock C. Arzneimittelforschung; 1996 Aug; 46(8):766-73. PubMed ID: 9125276 [Abstract] [Full Text] [Related]
2. Pharmacokinetics of estradiol and of estrone during application of a new 7-day estradiol transdermal patch with active matrix. Setnikar I, Rovati LC, Vens-Cappell B, Hilgenstock C. Arzneimittelforschung; 1998 Mar; 48(3):275-85. PubMed ID: 9553686 [Abstract] [Full Text] [Related]
3. Steady-state pharmacokinetics following application of a novel transdermal estradiol spray in healthy postmenopausal women. Morton TL, Gattermeir DJ, Petersen CA, Day WW, Schumacher RJ. J Clin Pharmacol; 2009 Sep; 49(9):1037-46. PubMed ID: 19628730 [Abstract] [Full Text] [Related]
4. Pharmacokinetics of percutaneous estradiol: a crossover study using a gel and a transdermal system in comparison with oral micronized estradiol. Scott RT, Ross B, Anderson C, Archer DF. Obstet Gynecol; 1991 May; 77(5):758-64. PubMed ID: 2014092 [Abstract] [Full Text] [Related]
5. Estradiol and estrone plasma levels during application of three strengths of a 7-day estradiol transdermal patch. Setnikar I, Rovati LC, Santoro A, Guillaume M, Mignot A, Renoux A, Gualano V. Arzneimittelforschung; 1999 Aug; 49(8):708-15. PubMed ID: 10483519 [Abstract] [Full Text] [Related]
6. Pharmacokinetics of estradiol and of estrone during application of three strengths of an estradiol transdermal patch with active matrix. Setnikar I, Rovati LC, Thebault JJ, Guillaume M, Mignot A, Renoux A, Gualano V. Arzneimittelforschung; 1997 Jul; 47(7):859-65. PubMed ID: 9272245 [Abstract] [Full Text] [Related]
7. Bioavailability of estradiol from two transdermal patches. Setnikar I, Rovati LC, Vens-Cappell B, Hilgenstock C. Arzneimittelforschung; 1996 Mar; 46(3):307-10. PubMed ID: 8901155 [Abstract] [Full Text] [Related]
8. Plasma profiles of transdermal 17 beta-estradiol delivered by two different matrix patches. A four-way cross-over study in postmenopausal women. Rohr UD, Ehrly AM, Kuhl H. Arzneimittelforschung; 1997 Jun; 47(6):761-7. PubMed ID: 9239456 [Abstract] [Full Text] [Related]
9. The effect of acute ethanol ingestion on estrogen levels in postmenopausal women using transdermal estradiol. Ginsburg ES, Walsh BW, Gao X, Gleason RE, Feltmate C, Barbieri RL. J Soc Gynecol Investig; 1995 Jun; 2(1):26-9. PubMed ID: 9420845 [Abstract] [Full Text] [Related]
10. The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status. Gupta P, Ozel B, Stanczyk FZ, Felix JC, Mishell DR. Menopause; 2008 Jun; 15(1):94-7. PubMed ID: 17882008 [Abstract] [Full Text] [Related]
11. Pharmacokinetics of weekly transdermal estradiol controlled delivery system in postmenopausal Chinese. Chen GS, Zhang MY, Wang Q, Ye JC. Zhongguo Yao Li Xue Bao; 1996 Sep; 17(5):407-10. PubMed ID: 9863160 [Abstract] [Full Text] [Related]
12. Characterization of a 7 day 17 beta-estradiol transdermal delivery system: pharmacokinetics in healthy postmenopausal women. Boyd RA, Zegarac EA, Eldon MA, Sedman AJ, Forgue ST. Biopharm Drug Dispos; 1996 Aug; 17(6):459-70. PubMed ID: 8866037 [Abstract] [Full Text] [Related]
13. [Bioavailability of 17 beta-estradiol after transdermal administration--dependence on the patch system]. Schmolling J, Kusche J, van der Ven H, Schander K. Zentralbl Gynakol; 1998 Aug; 120(3):121-5. PubMed ID: 9556902 [Abstract] [Full Text] [Related]
14. Minimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tablets. Eugster-Hausmann M, Waitzinger J, Lehnick D. Climacteric; 2010 Jun; 13(3):219-27. PubMed ID: 20423242 [Abstract] [Full Text] [Related]
16. Pharmacokinetics of orally administered estradiol valerate. Results of a single-dose cross-over bioequivalence study in postmenopausal women. Zimmermann H, Koytchev R, Mayer O, Börner A, Mellinger U, Breitbarth H. Arzneimittelforschung; 1998 Sep; 48(9):941-7. PubMed ID: 9793623 [Abstract] [Full Text] [Related]
17. Steady-state bioavailability of estradiol from two matrix transdermal delivery systems, Alora and Climara. Buch A, Shen L, Kelly S, Sahota R, Brezovic C, Bixler C, Powell J. Menopause; 1998 Sep; 5(2):107-12. PubMed ID: 9689205 [Abstract] [Full Text] [Related]
19. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Vehkavaara S, Silveira A, Hakala-Ala-Pietilä T, Virkamäki A, Hovatta O, Hamsten A, Taskinen MR, Yki-Järvinen H. Thromb Haemost; 2001 Apr; 85(4):619-25. PubMed ID: 11341495 [Abstract] [Full Text] [Related]
20. Serum concentrations of 17beta-estradiol and estrone after multiple-dose administration of percutaneous estradiol gel in symptomatic menopausal women. Brennan JJ, Lu Z, Whitman M, Stafiniak P, van der Hoop RG. Ther Drug Monit; 2001 Apr; 23(2):134-8. PubMed ID: 11294513 [Abstract] [Full Text] [Related] Page: [Next] [New Search]